First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)
First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment: A Multi-center Randomized Trial
Sponsor: Johnson & Johnson
Listed as NCT00392054, this PHASE3 trial focuses on Atrial Fibrillation and remains completed. Sponsored by Johnson & Johnson, it has been updated 10 times since 2006, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jun 2018 — Feb 2020 [monthly]
Unknown Status PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johnson & Johnson
- Population Health Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Acquaviva delle Fonti, Italy, Austin, United States, Bad Krozingen, Germany, Hamburg, Germany, Hamilton, Canada, London, Canada, Montreal, Canada, Newmarket, Canada, Prague, Czechia, Québec, Canada and 2 more location s